Urinary Tract Infection Due to Beta-lactamase-producing Enterobacteriaceae in Children
- Conditions
- Urinary Tract Infections
- Registration Number
- NCT02832258
- Lead Sponsor
- Fouad Madhi
- Brief Summary
Urinary tract infection due to Extended-spectrum beta-lactamase producing enterobacteriaceae (E-ESBL UTI) become a frequent problem. A too large variety in the prescription of antibiotics for E-ESBL UTI in children and absolute recommendations regarding the optimal treatment of E-ESBL is nearly impossible at this time.
Our aim was to describe the characteristics and treatments of urinary tract infections caused by Extended spectrum betalactamase-producing Enterobacteriaceae in children.
- Detailed Description
In this prospective observational study between March 2013 and March 2017, children (0 to 18 years) with ESBL-E UTI were enrolled in 24 pediatric departments in France. Clinical and biological characteristics, risk factors of infection of E-ESBL, first and second lines of antibiotic therapies were analyzed. The investigators used the Kaplan-Meier method to estimate the time to fever defervescence and hospitalization duration, and Log-rank test to assess equality of survivor functions. The investigators also analyzed the resistance patterns and molecular characterization of ESBL types in the isolates.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 590
- All inpatient or outpatient under 18 years with UTI (cystitis or febrile UTI)
- Clinical signs associated with a positive E-ESBL in urine culture dependent urine collection method as previously described (Stein R, EAU/ESPU guidelines) and an antibiotic treatment targeting this strain.
- Refusal to participate in the study
- Children with mixed microbial strains and repeated infections were excluded
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method First and second lines used antibiotic therapies at inclusion, at 3 days
- Secondary Outcome Measures
Name Time Method cytobacteriological examination of the urine results at inclusion, at 3 days urine analysis by regent strip method at inclusion Clinical characteristics (fewer, clinical sepsis) of E-ESBL UTI in children at inclusion Resistance patterns of ESBL types in the isolates at inclusion On the fisrt hundred urine samples
C reactive protein level of patient with E-ESBL UTI in children at inclusion Positive blood culture at inclusion Time to apyrexia (Kaplan-Meier method) at inclusion Length of hospital stay (Kaplan-Meier method) at inclusion Molecular characterization of ESBL types in the isolates at inclusion On the fisrt hundred urine samples
Clinical history of patient with E-ESBL UTI in children at inclusion procalcitonin level of patient with E-ESBL UTI in children at inclusion
Trial Locations
- Locations (24)
CHU Lenval
馃嚝馃嚪Nice, France
Antoine Becl猫re Hospital
馃嚝馃嚪Clamart, Ile-de France, France
Louis Mourier Hospital
馃嚝馃嚪Colombes, France
Jean Verdier Hospital
馃嚝馃嚪Bondy, Ile-de-France, France
CHI Cr茅teil
馃嚝馃嚪Cr茅teil, France
Centre Hospitalier de Dourdan
馃嚝馃嚪Dourdan, France
Andr茅 Mignot Hospital
馃嚝馃嚪Le Chesnay, Ile-de-France, France
Saint Camille Hospital
馃嚝馃嚪Bry-sur-Marne, France
Hopital Ambroise Par茅
馃嚝馃嚪Boulogne-Billancourt, France
CHU Le Havre
馃嚝馃嚪Le Havre, France
CHU Lyon
馃嚝馃嚪Lyon, France
CHU Le Kremlin-Bic锚tre
馃嚝馃嚪Le Kremlin-Bic锚tre, France
Roger Salengro Hospital
馃嚝馃嚪Lille, France
Centre Hospitalier G茅n茅ral de Longjumeau
馃嚝馃嚪Longjumeau, France
Centre Hospitalier de Meaux
馃嚝馃嚪Meaux, France
Robert Debr茅
馃嚝馃嚪Paris, France
Centre Hospitalier Marc Jacquet
馃嚝馃嚪Melun, France
CHU Rouen
馃嚝馃嚪Rouen, France
H么pital Necker
馃嚝馃嚪Paris, France
CHU Nantes
馃嚝馃嚪Nantes, France
Hospital Trousseau
馃嚝馃嚪Paris, France
Centre Hospitalier d'Orsay
馃嚝馃嚪Orsay, France
Centre Hospitalier Roubaix
馃嚝馃嚪Roubaix, France
H么pital Intercommunal de Villeneuve Saint-Georges
馃嚝馃嚪Villeneuve Saint-Georges, France